Close Menu

NEW YORK – Findings from a randomized, Phase II clinical trial suggest adding bevacizumab (Genentech's Avastin) to erlotinib (Tarceva from Genentech/Astellas) treatment does not extend progression-free survival for patients with EGFR-mutated, non-small cell lung cancer (NSCLC) compared to erlotinib alone.

"Compared with erlotinib, the combination did not result in a significant difference in PFS," first and corresponding author Thomas Stinchcombe, a medical oncologist and investigator at the Duke Cancer Institute, and his colleagues wrote.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jan
28

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.